New drug hopes to shrink Hard-to-Treat tumors
NCT ID NCT07306559
First seen Dec 29, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tests a new drug, BI 3820768, in adults with advanced germ cell, endometrial, or ovarian cancer that has not responded to prior treatments. The drug aims to help the immune system fight cancer. Participants receive weekly injections for two 3-week cycles, then every 3 weeks, and are monitored for up to 3 years to assess safety and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED RELAPSED OR REFRACTORY GERM CELL TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cliniques Universitaires Saint-Luc
NOT_YET_RECRUITINGBrussels, 1200, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clínica Universidad de Navarra - Madrid
NOT_YET_RECRUITINGMadrid, 28027, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
INS Paoli-Calmettes
NOT_YET_RECRUITINGMarseille, 13009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Indiana University
NOT_YET_RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Gustave Roussy
NOT_YET_RECRUITINGVillejuif, 94800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Japanese Foundation for Cancer Research
NOT_YET_RECRUITINGTokyo, Koto-ku, 135-8550, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Klinikum der Universität München AÖR
NOT_YET_RECRUITINGMünchen, 81377, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital East
NOT_YET_RECRUITINGChiba, Kashiwa, 277-8577, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Texas MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UZ Leuven
SUSPENDEDLeuven, 3000, Belgium
-
Universitätsklinikum Würzburg AÖR
NOT_YET_RECRUITINGWürzburg, 97078, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.